Drug-related mitochondrial optic neuropathies

Journal of Neuro-Ophthalmology

Volumn 33, Issue 2, 2013, Pages 172-178

  Wang, Michelle Y ^a   Sadun, Alfredo A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMPHENICOL; ERYTHROMYCIN; ETHAMBUTOL; LINEZOLID; STREPTOMYCIN; TOXIN;

CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG WITHDRAWAL; GENETIC DISORDER; HUMAN; NUTRITIONAL DEFICIENCY; OPTIC NERVE DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; VISUAL IMPAIRMENT;

ANTI-INFECTIVE AGENTS; HUMANS; MITOCHONDRIAL DISEASES; OPTIC NERVE DISEASES;

EID: 84879986335     PISSN: 10708022     EISSN: 15365166     Source Type: Journal    
DOI: 10.1097/WNO.0b013e3182901969     Document Type: Review

References (89)

1. Sadun AA. Mitochondrial optic neuropathies. J Neurol Neurosurg Psychiatry. 2002;72:423-425.
2. Sadun AA, Win PH, Ross-Cisneros FN, Walker SO, Carelli V. Leber's hereditary optic neuropathy differentially affects smaller axons in the optic nerve. Trans Am Ophthalmol Soc. 2000;98:223-235.
3. Carelli V, Ross-Cisneros F, Sadun AA. Mitochondrial dysfunction as a cause of optic neuropathies. Prog Retinal Eye Res. 2004;23:53-89.
4. Sadun AA. Acquired mitochondrial impairment as a cause of optic nerve disease. Tr Am Soc. 1998;96:881-923.
5. Rizzo JF III. Adenosine triphosphate deficiency: a genre of optic neuropathy. Neurology. 1995;45:11-16.
6. Carelli V, Ross-Cisneros FN, Sadun AA. Optic nerve degeneration and mitochondrial dysfunction: genetic and acquired optic neuropathies. Neurochem Int. 2002;40: 573-584.
7. Pan BX, Ross-Cisneros FN, Carelli V, Rue KS, Salomao SR, Moraes-Filho MN, Moraes MN, Berezovsky A, Belfort R Jr, Sadun AA. Mathematically modeling the involvement of axons in Leber's hereditary optic neuropathy. Invest Ophthalmol Vis Sci. 2012;53:7608-617.
8. Zoumalan CI, Agarwal M, Sadun AA. OCT can measure axonal loss in patients with ethambutol-induced optic neuropathy. Graefes Arch Clin Exp Ophthalmol. 2005;243:410-416.
9. Barboni P, Savini G, Valentino ML, Montagna P, Cortelli P, De Negri AM, Sadun F, Bianchi S, Longanesi L, Zanini M, de Vivo A, Carelli V. Retinal nerve fiber layer evaluation by optical coherence tomography in Leber's hereditary optic neuropathy. Ophthalmology. 2005;112:120-126.
10. Salmon JF, Carmichael TR, Welsh NH. Use of contrast sensitivity measurement in the detection of subclinical ethambutol toxic optic neuropathy. Br J Ophthalmol. 1987;71:192-196.
11. Barboni P, Carbonelli M, Savini G, Foscarini B, Parisi V, Valentino ML, Carta A, De Negri A, Sadun F, Zeviani M, Sadun AA, Schimpf S, Wissinger B, Carelli V. OPA1 mutations associated with dominant optic atrophy influence optic nerve head size. Ophthalmology. 2010;117:1547-1553.
12. Ito Y, Nakamura M, Yamakoshi T, Lin J, Yatsuya H, Terasaki H. Reduction of inner retinal thickness in patients with autosomal dominant optic atrophy associated with OPA1 mutations. Invest Ophthalmol Vis Sci. 2007;48:4079-4086.
13. Kim TW, Hwang JM. Stratus OCT in dominant optic atrophy: features differentiating it from glaucoma. J Glaucoma. 2007;16:655-658.
14. Milea D, Sander B, Wegener M, Jensen H, Kjer B, Jørgensen TM, Lund-Andersen H, Larsen M. Axonal loss occurs early in dominant optic atrophy. Acta Ophthalmol. 2010;88:342-346.
15. McMartin KE, Ambre JJ, Tephly TR. Methanol poisoning in human subjects. Role for formic acid accumulation in metabolic acidosis. Am Med. 1980;8:414-418.
16. Sobel RS, Yanuzzi LA. Optic nerve toxicity. A classification. In: Singerman I, Jampol LM, eds. Retinal and Choroidal Manifestations of Disease. Baltimore, MD: Williams & Wilkins, 1991:226-250.
17. Kozak SF, Inderlied CB, Hsu HY, Heller KB, Sadun AA. The role of copper on ethambutol's antimicrobial action and implications for ethambutol-induced optic neuropathy. Diagn Microbiol Infect Dis. 1998;30:83-87.
18. Chan JW, Castellanos A. Infliximab and anterior optic neuropathy: case report and review of the literature. Graefes Arch Clin Exp Ophthalmol. 2010;248:283-287.
19. World Health Organization. Global Tuberculosis Control: Surveillance, Planning, Financing: WHO Report 2008. WHO/HTM/TB/2008.393. Geneva, Switzerland: World Health Organization, 2008.
20. Sadun AA, Wang MY. Ethambutol optic neuropathy: how we can prevent 100,000 new cases of blindness each year. J Neuroophthalmol. 2008;28:265-268.
21. Yoon YH, Jung KH, Sadun AA, Shin HC, Koh JY. Ethambutolinduced vacuolar changes and neuronal loss in rat retinal cell culture: mediation by endogenous zinc. Toxicol Appl Pharmacol. 2000;162:107-114.
22. Becker DA, Balcer LJ, Galetta SL. The neurological complications of nutritional deficiency following bariatric surgery. J Obes. 2012 2012:608534.
23. Pineles SL, Wilson CA, Balcer LJ, Slater R, Galetta SL. Combined optic neuropathy and myelopathy secondary to copper deficiency. Surv Ophthalmol. 2010;55:386-392.
24. Leopold IH. Zinc deficiency and visual impairment. Am J Ophthalmol. 1978;85:871-875.
25. Delacoux E, Moreau Y, Godefroy A, Evstigneef T. Prevention of ocular toxicity of ethambutol: study of zincaemia and chromatic analysis. J Fr Ophtalmol. 1978;1:191-196.
26. De Palma P, Franco F, Bragliani G, Michetti L, Marescotti A, Pirazzoli G, Fiorenza M. The incidence of optic neuropathy in 84 patients treated with ethambutol. Metab Pediatr Syst Ophthalmol. 1989;2:80-82.
27. Chung H, Yoon YH, Hwang JJ, Cho KS, Koh JY, Kim JG. Ethambutol-induced toxicity is mediated by zinc and lysosomal membrane permeabilization in cultured retinal cells. Toxicol Appl Pharmacol. 2009;235:163-170.
28. Carr RE, Henkind P. Ocular manifestations of ethambutol, toxic amblyopia after administration of an experimental antituberculous drug. Arch Ophthalmol. 1962;67:566-571.
29. Citron K. Ethambutol. A review with special reference to ocular toxicity. Tubercle. 1969;50(suppl):32-36.
30. Leibold JE. Drugs having a toxic effect on the optic nerve. Int Ophthalmol Clin. 1971;11:137-157.
31. Bronte Stewart J, Pettigrew AR, Foulds WS. Toxic optic neuropathy and its experimental production. Trans Ophthalmol Soc UK. 1976;96:355-358.
32. Yoshikawa T, Nagami P. Adverse drug interactions in TB therapy: risks and recommendations. Geriatrics. 1982;37:61-68.
33. Fledelius HC, Petrera JE, Skjødt K, Trojaborg W. Ocular ethambutol toxicity. Acta Ophthalmol. 1987;65:251-255.
34. Kahana LM. Toxic ocular effects of ethambutol. Can Med Assoc J. 1987;137:212-216.
35. Smith JL. Should ethambutol be barred? J Clin Neuroophthalmol. 1987;7:84-86.
36. Kahana LM. Ethambutol and the eye. Lancet. 1988;2:627.
37. Rahman M, Nizam R. Ethambutol toxic neuroretinopathy in Bangladesh. Pakistan J Ophthalmol. 1989;5:37-40.
38. Kumar A, Sandramouli S, Verma L, Tewari HK, Khosla PK. Ocular ethambutol toxicity: is it reversible? J Clin Neuroophthalmol. 1993;13:15-17.
39. Choi SY, Hwang JM. Optic neuropathy associated with ethambutol in Koreans. Korean J Ophthalmol. 1997;11: 106-110.
40. Murray FJ. U.S. Public Health Service experience with ethambutol. International Congress of Chemotherapy, Vienna. 1967;6:33-382.
41. Alvarez KL, Krop LC. Ethambutol-induced ocular toxicity revisited. Ann Pharmacother. 1993;27:102-103.
42. Thomas RJ. Neurotoxicity of antibacterial therapy. South Med J. 1994;87:869-874.
43. Chuenkongkaew W, Samsen P, Thanasombatsakul N. Ethambutol and optic neuropathy. J Med Assoc Thai. 2003;86:622-625.
44. Chan RY, Kwok AK. Ocular toxicity of ethambutol. Hong Kong Med J. 2006;12:56-60.
45. Santaella RM, Fraunfelder FW. Ocular adverse effects associated with systemic medications: recognition and management. Drugs. 2007;67:75-93.
46. Asayama T. Two cases of bitemporal hemianopsia due to ethambutol. Jpn J Clin Ophthalmol. 1969;23:1209-1212.
47. Kho RC, Al-Obailan M, Arnold AC. Bitemporal visual field defects in ethambutol-induced optic neuropathy. J Neuroophthalmol. 2011;31:121-126.
48. Lim SA. Ethambutol-associated optic neuropathy. Ann Acad Med Singapore. 2006;35:274-278.
49. Chen HY, Lai SW, Muo CH, Chen PC, Wang IJ. Ethambutolinduced optic neuropathy: a nationwide population-based study from Taiwan. Br J Ophthalmol. 2012;96:1368-1371.
50. World Health Organization. Treatment of Tuberculosis: Guidelines for National Programmes, 3rd edition. WHO/CDS/TB/2003.313. Geneva, Switzerland: World Health Organization, 2003.
51. Griffith DE, Brown-Elliott BA, Shepherd S, McLarty J, Griffith L, Wallace RJ Jr. Ethambutol ocular toxicity in treatment regimens for Mycobacterium avium complex lung disease. Am J Respir Crit Care Med. 2005;172:250-253.
52. Barron GJ, Tepper L, Iovine G. Ocular toxicity from ethambutol. Am J Ophthalmol. 1974;77:256-260.
53. Citron KM, Thomas GO. Ocular toxicity from ethambutol. Thorax. 1986;41:737-739.
54. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, Jasmer RM, Koppaka V, Menzies RI, O'Brien RJ, Reves RR, Reichman LB, Simone PM, Starke JR, Vernon AA; American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167:603-662.
55. World Health Organization. Ethambutol Efficacy and Toxicity. Literature Review and Recommendation for Daily and Intermittent Dosage in Children. Geneva, Switzerland: WHO, 2006.
56. Donald PR, Maher D, Maritz JS, Qazi S. Ethambutol dosage for the treatment of children: literature review and recommendations. Int J Tuberc Lung Dis. 2006;10:1318-1330.
57. Kim U, Hwang JM. Early stage ethambutol optic neuropathy: retinal nerve fiber layer and optical coherence tomography. Eur J Ophthalmol. 2009;19:466-469.
58. Talbert Estlin KA, Sadun AA. Risk factors for ethambutol optic toxicity. Int Ophthalmol. 2010;30:63-72.
59. Tsai RK, Lee YH. Reversibility of ethambutol optic neuropathy. J Ocul Pharmacol Ther. 1997;13:473-477.
60. Woung LC, Jou JR, Liaw SL. Visual function in recovered ethambutol optic neuropathy. J Ocul Pharmaco Ther. 1995;11:411-419.
61. De Vita EG, Miao M, Sadun AA. Optic neuropathy in ethambutol treated renal tuberculosis. J Clin Neuroophthalmol. 1987;7:77-83.
62. Cornblath WT, Clavert PC. Best catch from NANOSNET. II. Monitoring for ethambutol optic nerve toxicity. J Neuroophthal. 2002;22:124-125.
63. Fraunfelder FW, Sadun AA, Wood T. Update on ethambutol optic neuropathy. Expert Opin Drug Saf. 2006;5:615-618.
64. Kandel H, Adhikari P, Shrestha GS, Ruokonen EL, Shah DN. Visual function in patients on ethambutol therapy for tuberculosis. J Ocul Pharmacol Ther. 2012;28:174-178.
65. Menon V, Jain D, Saxena R, Sood R. Prospective evaluation of visual function for early detection of ethambutol toxicity. Br J Ophthalmol. 2009;93:1251-1254.
66. Chai SJ, Foroozan R. Decreased retinal nerve fibre layer thickness detected by optical coherence tomography in patients with ethambutol-induced optic neuropathy. Br J Ophthalmol. 2007;91:895-897.
67. Harley RD, Huang NN, Macri CH, Green WR. Optic neuritis and optic atrophy following chloramphenicol in cystic fibrosis patients. Trans Am Acad Ophthalmol Otolaryngol. 1970;74:1011-1031.
68. Gilman AG, Goodman LS, Rail TW, Murad F, eds. Goodman and Gilman's the Pharmacological Basis of Therapeutics, 7th edition. New York, NY: Macmillan, 1985:1179-1183.
69. Smith U, Smith DS, Yunis AA. Chloramphenicol-related changes in mitochondrial ultrastructure. J Cell Sci. 1970;7:501-521.
70. Godel V, Nemet P, Lazar M. Chloramphenicol optic neuropathy. Arch Ophthalmol. 1980;98:1417-1421.
71. Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis. 2003;36:159-168.
72. Fiscella RG, Lai WW, Buerk B, Khan M, Rodvold KA, Pulido JS, Labib S, Shapiro MJ, Blair NP. Aqueous and vitreous penetration of linezolid (Zyvox) after oral administration. Ophthalmology. 2004;111:1191-1195.
73. Rucker JC, Hamilton SR, Bardenstein D, Isada CM, Lee MS. Linezolid-associated toxic optic neuropathy. Neurology. 2006;66:595-598.
74. McKinley SH, Foroozan R. Optic neuropathy associated with linezolid treatment. J Neuroophthalmol. 2005;25:18-21.
75. Saijo T, Hayashi K, Yamada H, Wakakura M. Linezolid-induced optic neuropathy. Am J Ophthalmol. 2005;139:1114-1116.
76. Javaheri M, Khurana RN, O'hearn TM, Lai MM, Sadun AA. Linezolid-induced optic neuropathy: a mitochondrial disorder? Br J Ophthalmol. 2007;91:111-115.
77. De Vriese AS, Coster RV, Smet J, Seneca S, Lovering A, Van Haute LL, Vanopdenbosch LJ, Martin JJ, Groote CC, Vandecasteele S, Boelaert JR. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis. 2006;42:1111-1117.
78. Yu-Wai-Man P, Griffiths PG, Chinnery PF. Mitochondrial optic neuropathies - disease mechanisms and therapeutic strategies. Prog Retin Eye Res. 2011;30:81-114.
79. Walker GF. Blindness during streptomycin and chloramphenicol therapy. Br J Ophthalmol. 1961;45:555-559.
80. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med. 1995;1:417-422.
81. Samuels DC. Mitochondrial AZT metabolism. IUBMB Life. 2006;58:403-408.
82. Scruggs ER, Dirks Naylor AJ. Mechanisms of zidovudineinduced mitochondrial toxicity and myopathy. Pharmacology. 2008;82:83-88.
83. Shaikh S, Ta C, Basham AA, Mansour S. Leber hereditary optic neuropathy associated with antiretroviral therapy for human immunodeficiency virus infection. Am J Ophthalmol. 2001;131:143-145.
84. Mackey DA, Fingert JH, Luzhansky JZ, McCluskey PJ, Howell N, Hall AJ, Pierce AB, Hoy JF. Leber's hereditary optic neuropathy triggered by antiretroviral therapy for human immunodeficiency virus. Eye (Lond). 2003;17:312-317.
85. Ikeda A, Ikeda T, Ikeda N, Kawakami Y, Mimura O. Leber's hereditary optic neuropathy precipitated by ethambutol. Jpn J Ophthalmol. 2006;50:280-283.
86. Seo JH, Hwang JM, Park SS. Antituberculosis medication as a possible epigenetic factor of Leber's hereditary optic neuropathy. Clin Experiment Ophthalmol. 2010;38:363-366.
87. Luca CC, Lam BL, Moraes CT. Erythromycin as a potential precipitating agent in the onset of Leber's hereditary optic neuropathy. Mitochondrion. 2004;4:31-26.
88. Guillet V, Chevrollier A, Cassereau J, Letournel F, Gueguen N, Richard L, Desquiret V, Verny C, Procaccio V, Amati-Bonneau P, Reynier P, Bonneau D. Ethambutol-induced optic neuropathy linked to OPA1 mutation and mitochondrial toxicity. Mitochondrion. 2010;10:115-124.
89. Miller NR. Toxic and deficiency optic neuropathies. In: Miller NR, ed. Walsh and Hoyt's Clinical Neuro-ophthalmology, Vol. 1, 6th edition. Baltimore, MD: Williams & Wilkins, 2005:448-463.